Professional Documents
Culture Documents
Biosensors develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures.
Performance
Risk Assessment
Conclusion
Our Milestones
1990 2005 2007 2008 2010 2011 Company Founded Listed on SGX Mainboard Acquired 50% interest in JWMS Received CE Mark for BioMatrix Launched in Europe and Asia Hony Capital acquired majority stake in Biosesor Raised S$200 million (Alantis & Ever Union) Fully acquired JWMS
Performance
Risk Assessment
Conclusion
Our Presence
More about us
Market Capitalisation: S$2.25 billion Major shareholders:
Shandong Weigao Hony Capital Fidelity Atlantis EverUnion
Management Team
Yoh Chie Lu, founder and Chairman
President of Asia-Pacific division for BOC
76%
Others
Source: Peripheral Vascular & Interventional Cardiology Devices Market (2011 2016) Global Trends & Competitive Analysis Report Code: MD 1752
Introduction
Risk Assessment
Conclusion
8.9
Introduction
Risk Assessment
Conclusion
Competitive Edge
The First Biodegradable DES - BioMatrix Strong clinical trial results Access to Chinas emerging market JWMS Next generation of DES- BioFreedom Strategic acquisition for technology development CardioMind Inc. AXXESSTM (Devax, Inc.)
Introduction Risk Assessment Conclusion
Financial Highlights
Revenue EPS
34.79%
Profit ROE
32.60%
34.98%
Introduction
48.42%
Risk Assessment Conclusion
Liquidity: High
GEARING RATIO COMPARISON
60 50 40 30 20 10 0 2009 BIOSENSORS 2010 BOSTON SCIENTIFIC 2011 MEDTRONIC 20.18 9.08 45.19 48.11 48.11 48.14 48.14 37.53 37.53 6.00 5.00 4.00 3.00 2.07 2.00 1.00 0.00 2009 BIOSENSORS 2010 BOSTON SCIENTIFIC 2011 MEDTRONIC 1.06 1.52 2.17 1.39 2.37 1.72
1.92
Introduction
Risk Assessment
Conclusion
ROE Comparison
ROE COMPARISON
25.00% 21.11% 20.00% 15.70% 15.00% 11.43% 10.00% 5.00% 0.00% -1.08% -5.00% -10.00% -15.00% BIOSENSORS BOSTON SCIENTIFIC MEDTRONIC -8.66% 2009 2010 2011 3.88% 2.16% 19.39%
-9.07%
Introduction
Risk Assessment
Conclusion
BIOSENSORS
Introduction
Risk Assessment
Conclusion
Growth Strategy
Expanding in China JW Medical Service Growing market Penetrating the United States Largest global DES market Expanding Product Portfolio
Introduction
Risk Assessment
Conclusion
Risk Assessment
Preferred supplier agreements Declining prices of DES Competition from local manufacturers Regulatory Requirement
Introduction
Performance
Conclusion
3 Reasons to Invest
We make dollars and stents Every 2 seconds someone has a heart attack Access to growing markets
Introduction
Performance
Q&A